Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Summary
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
425
Start Date
2026-07
Completion Date
2027-08
Last Updated
2026-06-26
Healthy Volunteers
No
Conditions
Interventions
HRS9531 Tablet
HRS9531 tablet.
HRS9531 Tablet Placebo
HRS9531 tablet placebo.
Locations (2)
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Nanjing Drum Tower hospital
Nanjing, Jiangsu, China